Tirzepatide

Concentration: Available in 10 mg,20 mg,per vial (lyophilized powder).

Physical Form: White lyophilized powder in sterile vial.

Purity: ≥98% (analytical HPLC).

Identity Confirmation: MS and amino acid analysis verified.

Stability: Formulated as a stable acetate salt for extended shelf-life.

Dual agonist mechanism: Tirzepatide uniquely activates both GIP and GLP-1 receptors, leading to enhanced insulin release and appetite suppressionnejm.org. It mimics natural incretin hormones, improving blood sugar control in diabetes models.

Weight loss efficacy: In studies, Tirzepatide produced markedly greater weight reduction than selective GLP-1 agonists. Subjects achieved up to ~24% body weight loss over ~48 weeksgoodrx.com, highlighting its potential in obesity research.

Metabolic benefits: Beyond glucose lowering, it improved insulin sensitivity and lipid profiles in preclinical modelsnejm.org. It also showed cardioprotective effects related to weight loss and improved metabolic health in animal studiespmc.ncbi.nlm.nih.gov.

Mode of action: By engaging the GIP receptor (often underutilized by other drugs) along with GLP-1R, it may restore beta-cell responsiveness and induce greater satietynejm.orggoodrx.com. Its “imbalanced” co-agonism favors GLP-1 effects while retaining GIP’s insulinotropic actionfrontiersin.org.

Clinical status: Tirzepatide is FDA-approved for type 2 diabetes and under investigation for chronic weight management. It has demonstrated significant HbA1c reductions and weight loss in Phase 3 trials

• Reconstitute the lyophilized powder with sterile Bacteriostatic Water or USP sterile water (volume per vial per desired concentration). Gently swirl until dissolved – do not shake vigorously.
  
• Concentration note: Higher-dose vials (e.g. 60 mg) may require a larger diluent volume to fully dissolve. Typical reconstitution yields ≥5 mg/mL peptide concentration.
  
• Use aseptic technique. If solution is not clear, it can be filtered through a 0.22 µm syringe filter.
  
• Once reconstituted, potency remains stable for short-term use (see Storage/Stability). Record the date of reconstitution for reference.
  

Lyophilized (unreconstituted): Stable for ≥24 months when stored at –20 °C. For short-term (<3 months), store at 2–8 °C. Keep the vial tightly sealed, protected from light and moisture.

Reconstituted solution: Stable for up to 14 days at 2–8 °C. For longer preservation, aliquot and freeze at –20 °C (avoid repeated freeze-thaw cycles).

Shipping: Shipped on ice packs to maintain stability. Lyophilized Tirzepatide tolerates room temperature for brief periods (≤1 week) without significant degradation.

Handling precautions: Bring to room temperature before reconstitution to avoid condensation. Do not expose reconstituted peptide to temperatures >25 °C.

For research use only. Not for human consumption, therapeutic, or diagnostic use.

All testing involving Tirzepatide should be under appropriate laboratory and safety protocols. Researchers must comply with local regulations governing investigational peptides.